TOKYO (Reuters) – A Japanese health ministry panel on Thursday recommended approval for Eli Lilly’s dementia treatment donanemab.
Formal approval is expected shortly after the panel’s vote, which would make the drug Japan’s second approved treatment for Alzheimer’s disease after Leqembi, developed by Eisai and Biogen.
Donanemab, sold under the brand name Kisunla, was approved by the U.S. Food and Drug Administration early last month.
(Reporting by Rocky Swift; Editing by Andrew Heavens)
